FDA approves BRINSUPRI as first treatment for non-cystic fibrosis bronchiectasis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Insmed (INSM) PT Raised to $148 at Jefferies
August 12, 2025 2:49 PM EDTJefferies analyst Kelly Shi raised the price target on Insmed (NASDAQ: INSM) to $148.00 (from $129.00) while maintaining a Buy rating.
The analyst comments "INSM has been an attractive commercial biotech story in pulmonary space w/ repeated clinical success, winning an FDA approval today w/... More
